The ETV2 antibody is a crucial tool in studying the ETS variant transcription factor 2 (ETV2), a member of the ETS family of DNA-binding proteins. ETV2. also known as ER71 or ETSRP, plays a pivotal role in embryonic vascular development and hematopoiesis. It acts as a master regulator of endothelial cell differentiation, directly controlling genes involved in blood vessel formation. Research has shown that ETV2 is indispensable for vasculogenesis in vertebrates, with knockout models demonstrating lethal defects in vascular and hematopoietic systems during early embryogenesis.
The ETV2 antibody enables detection and quantification of this transcription factor in various experimental settings, including Western blotting, immunohistochemistry, and flow cytometry. Its applications span developmental biology, regenerative medicine, and cancer research, particularly in studies investigating angiogenesis, endothelial cell reprogramming, and vascular abnormalities. Commercially available ETV2 antibodies are typically raised against specific epitopes of human or mouse ETV2 protein, with validation in knockout controls to confirm specificity.
Recent studies also explore ETV2's role in adult endothelial maintenance and its potential as a therapeutic target for vascular diseases. The antibody's utility extends to characterizing induced pluripotent stem cell-derived endothelial cells and modeling vascular disorders. Cross-reactivity varies by product, requiring careful selection based on experimental models. As vascular biology remains a hotbed for translational research, ETV2 antibodies continue to be vital reagents for unraveling mechanisms of vascular development and pathology.